Navigation Links
Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity
Date:4/2/2011

ORLANDO, Fla. The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

The research, presented by Johanna Bendell, M.D., tests a combination of GDC-0973, which inhibits MEK1/2 and GDC-0941, which inhibits PI3K. Bendell, director of Gastrointestinal Oncology Research and associate director of the drug development unit at the Sarah Cannon Research Institute in Nashville, said the RAS/RAF/MEK and PI3K pathways are altered in most tumors.

"Combining agents that block multiple pathways in tumor cells is likely the future of targeted therapy in cancer medicine. Blocking two pathways that interact with each other has the potential to have more anti-cancer activity than blocking either pathway alone," says Bendell.

The researchers enrolled 27 patients who received the combination of different doses of GDC-0973 and GDC-0941 on a daily 21 day on/7 day off schedule. The most common side effects seen were diarrhea, fatigue, rash, nausea, vomiting, decreased appetite and taste changes. Most of these side effects were mild.

Several patients have demonstrated decreases in tumor size, including two patients with melanoma, one with prostate cancer, two with non-small cell lung cancer. One patient with lung cancer and two patients with melanoma had stable disease over six months. The study is ongoing.

"We are very encouraged by this early data. We are able to give these agents together safely and we are seeing early signs of anti-cancer activity," said Bendell.

This abstract will be presented at an AACR press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can participate using the following information:

  • U.S. & Canada: (888) 647-7462
  • International: (201) 604-0169
  • Access Code: 244078


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Combining resistance and endurance training best for heart health
2. Combining medication and psychosocial treatments may benefit patients with early-stage schizophrenia
3. Combining radiation therapy, chemotherapy safely treats head and neck cancer patients
4. Study provides molecular rationale for combining targeted agents to treat breast cancer
5. Visual prostheses: Symposium to explore combining functional endpoints
6. Combining 2 peptide inhibitors might block tumor growth
7. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
8. JAK inhibitors producing significant response in myelofibrosis patients
9. Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate
10. Protein Appears Key to Intestinal Balance
11. How health care is paid for appears to impact outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Dr. David ... in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated ... is an online directory that recognizes local physicians and dentists who have earned ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for ... expert sit stand solutions representative to the Minneapolis Home and Garden Show which is ... event that is garnering national attention is the Minneapolis Convention Center. , From ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company ... announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: